Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction

Mark R. Goldstein

doi:10.7326/0003-4819-134-1-200101020-00021

Letters |2 January 2001

Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction

Mark R. Goldstein, MD

Article, Author, and Disclosure Information

TO THE EDITOR:

Grady and colleagues' interesting report (1) from HERS demonstrated that postmenopausal estrogen and progestin therapy increased the risk for venous thromboembolism nearly threefold in women with established coronary heart disease. Unexpectedly, the risk for venous thromboembolism was decreased by half in the women who were taking statin drugs.

In the original HERS report (2), treatment with estrogen and progestin over a 4.1-year period did not reduce the overall rate of coronary heart disease events despite a favorable effect on lipoproteins. In fact, event rates were significantly higher during the first year in the estrogen–progestin group. This suggests an initial increase in the rate of arterial thromboembolism in that group.

FULL TEXT

PDF

Not Available

2001 American College of Physicians

Letters |2 January 2001

Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction

See Also

Content

Information For

Services

Awards and Cover

Other Resources

Follow Annals On

Letters |2 January 2001

Hormone Therapy and Risk for Venous Thromboembolism: Comments and Correction

See Also

Content

Information For

Services

Awards and Cover

Other Resources

Follow Annals On

You need a subscription to this content to use this feature.